

Progression-free survival after first-line treatment in endometrial cancer patients: a real-world perspective from Brazil and Argentina


Gabriela Abreu, PhD¹; Juliana Queiroz, MSc¹; Thiago Luiz Nogueira da Silva, PhD¹; Claudia Soares, MD, PhD¹; Patricia Menezes, MBA¹; Mariano Carrizo, MD²; Paula Scibona, MD³; Ventura A Simonovich, MD³; María C Riggi, MD³; Florencia Cravero, MD³; Graziela Bernardino, MBA¹; Tatiana Pires, PhD¹; Andre Luiz Alves Ribeiro de Souza, MBA⁴; Laura Jotimlansky, MD²

¹GSK, Rio de Janeiro, Brazil; ²GSK, Buenos Aires, Argentina; ³Hospital Italiano de Buenos Aires, Buenos Aires, Argentina; ⁴Orizon, Rio de Janeiro, Brazil

Aim

To describe treatment patterns and healthcare outcomes of patients with endometrial cancer (EC) who received first-line (1L) platinum-based therapy (PBT) in Argentina and Brazil

Endometrial Cancer Health Outcomes Study in Argentina (ECHOS-A)




Study Design


- Retrospective cohort studies
- Records of privately insured patients
- Analysis of patients receiving 1L PBT

*Surgery, radiotherapy, or systemic therapy (chemotherapy, hormone therapy, or immunotherapy).


Endometrial Cancer Health Outcomes Study in Brazil (ECHOS-B)




Results




Among patients receiving 1L PBT (n=146)




Risk of progression




Progression-free survival (PFS[†])




PFS[†] by FIGO staging




*36% lost to follow-up; †Death was included as progression.




Among patients receiving 1L PBT (n=520)



Risk of progression



PFS[†]



*59% lost to follow-up; †Death was included as progression.

Background

- Despite being the **sixth most common cancer** among women worldwide,¹ **real-world data** concerning treatment patterns and outcomes in **EC**, particularly in Latin America, are **scarce**.^{2,3}
- Efforts to gain **deeper insights** into treatment patterns and healthcare outcomes in this context are **crucial** for highlighting **unmet medical needs** and **improving patient care**

Conclusion

High progression rates were observed for patients with EC receiving 1L PBT

Risk estimates suggest **most progressions** occurred within **2 years**, with high utilization of subsequent systemic therapy

Treatment approaches **preventing or delaying EC progression** beyond what is achievable with PBT are needed

Abbreviations

1L, first line; EC, endometrial cancer; ECHOS, Endometrial Cancer Health Outcomes Study; FIGO, International Federation of Gynecology and Obstetrics; PBT, platinum-based therapy; PFS, progression-free survival; SD, standard deviation.

References

1. World Cancer Research Fund International. <https://www.wcrf.org/cancer-trends/endometrial-cancer-statistics/> (accessed March 21, 2024).
2. Brüggmann D et al. *J Transl Med* 2020;18:386.
3. Paulino E and de Melo AC. *Rev Bras Ginecol Obstet* 2023;45:e401-e408.

Acknowledgments

Medical writing support was provided by Pallavi Patel, PhD, of Luna, OPEN Health Communications, and was funded by GSK, in accordance with Good Publication Practice (GPP) guidelines (www.ismpp.org/gpp-2022).

Disclosures

This study was funded by GSK (study ID: 221709). The authors declare the following real or perceived conflicts of interest during the past 3 years in relation to this presentation: GA, JQ, and TLNS are complementary employees of GSK and do not hold stocks or shares. CS, PM, MC, GB, TP, and LJ are employees of and hold stocks in GSK. MCR reports receiving speaker fees from AstraZeneca and GSK. PS, VAS, and FC have no conflicts of interest to declare. ALARS was an employee of Orizon at the time of the study.



SCAN ME